SCOPUS 정보 검색 플랫폼

New England Journal of Medicine

Volumn 361, Issue 19, 2009, Pages 1901-1903

End run around epo

(1) Bunn, H Franklin a

a BRIGHAM AND WOMEN S HOSPITAL (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CORTICOSTEROID; CYCLOSPORIN; ERYTHROPOIETIN RECEPTOR; IMMUNOGLOBULIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RECOMBINANT DNA TECHNOLOGY; THROMBOSIS; TUMOR GROWTH;

EID: 70350757860 PISSN: 00284793 EISSN: 15334406 Source Type: Journal
DOI: 10.1056/NEJMe0908186 Document Type: Editorial

Times cited : (7)

References (10)

1
- 0022980521
- Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis
- Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2:1175-1178
- (1986) Lancet , vol.2 , pp. 1175-1178
- Winearls, C.G.¹ Oliver, D.O.² Pippard, M.J.³ Reid, C.⁴ Downing, M.R.⁵ Cotes, P.M.⁶

2
- 0023120533
- Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial
- Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-78
- (1987) N Engl J Med , vol.316 , pp. 73-78
- Eschbach, J.W.¹ Egrie, J.C.² Downing, M.R.³ Browne, J.K.⁴ Adamson, J.W.⁵

3
- 4644351840
- Pure red-cell aplasia and epoetin therapy
- Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351:1403-1408
- (2004) N Engl J Med , vol.351 , pp. 1403-1408
- Bennett, C.L.¹ Luminari, S.² Nissenson, A.R.³

4
- 70350774297
- A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia
- Macdougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009;361:1848-1855
- (2009) N Engl J Med , vol.361 , pp. 1848-1855
- Macdougall, I.C.¹ Rossert, J.² Casadevall, N.³

5
- 33846669860
- Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis
- DOI 10.1016/S0140-6736(07)60194-9, PII S0140673607601949
- Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381-388 (Pubitemid 46188479)
- (2007) Lancet , vol.369 , Issue.9559 , pp. 381-388
- Phrommintikul, A.¹ Haas, S.J.² Elsik, M.³ Krum, H.⁴

6
- 33646905411
- Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients
- DOI 10.1093/jnci/djj189
- Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-714 (Pubitemid 43821788)
- (2006) Journal of the National Cancer Institute , vol.98 , Issue.10 , pp. 708-714
- Bohlius, J.¹ Wilson, J.² Seidenfeld, J.³ Piper, M.⁴ Schwarzer, G.⁵ Sandercock, J.⁶ Trelle, S.⁷ Weingart, O.⁸ Bayliss, S.⁹ Djulbegovic, B.¹⁰ Bennett, C.L.¹¹ Langensiepen, S.¹² Hyde, C.¹³ Engert, A.¹⁴

7
- 60149101104
- What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway?
- Besarab A, Frinak S, Yee J. What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway? Adv Chronic Kidney Dis 2009;16:131-142
- (2009) Adv Chronic Kidney Dis , vol.16 , pp. 131-142
- Besarab, A.¹ Frinak, S.² Yee, J.³

8
- 67649708228
- Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia
- Singh AK, Himmelfarb J, Szczech LA. Resolved: targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia. J Am Soc Nephrol 2009;20:1436-1443
- (2009) J Am Soc Nephrol , vol.20 , pp. 1436-1443
- Singh, A.K.¹ Himmelfarb, J.² Szczech, L.A.³

9
- 34250349152
- Weighing the hazards of erythropoiesis stimulation in patients with cancer
- Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 2007;356:2445-2448 (Pubitemid 46919767)
- (2007) New England Journal of Medicine , vol.356 , Issue.24 , pp. 2445-2448
- Khuri, F.R.¹

10
- 53549097076
- Erythropoietin-mediated tissue protection: Reducing collateral damage from the primary injury response
- Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008;264:405-432
- (2008) J Intern Med , vol.264 , pp. 405-432
- Brines, M.¹ Cerami, A.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.